Related Experiment Video

Updated: Feb 16, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

Underutilization of Aldosterone Antagonists in Heart Failure

Shanise J Patterson1, Anne B Reaves1,2, Elizabeth A Tolley2

  • 1Methodist University Hospital, USA.

Hospital Pharmacy
|December 26, 2017
PubMed

Insights

Aldosterone antagonists (AAs) are underused in heart failure (HF) treatment, with only 31% of eligible patients receiving this guideline-recommended therapy. Despite underutilization, AA use did not significantly impact 30- or 90-day readmission rates in this study.

Area of Science:

  • Cardiology
  • Pharmacology
  • Health Services Research

Background:

  • Aldosterone antagonists (AAs) are proven to reduce morbidity, mortality, and hospital readmissions in heart failure (HF).
  • Current ACCF/AHA guidelines recommend AA use in HF patients with ejection fraction ≤35% unless contraindicated.
  • Previous studies indicate significant underuse of AAs in clinical practice.

Purpose of the Study:

  • To assess the proportion of HF patients receiving guideline-consistent AA therapy.
  • To identify patients receiving AA therapy inconsistently with guidelines.
  • To evaluate 30- and 90-day readmission rates associated with AA use.

Main Methods:

  • Retrospective chart review of 346 HF admissions at an inner-city academic medical center.
  • Data collected from August 2011 to June 2013.
  • Analysis of AA discharge prescription and patient readmission data.

Main Results:

  • Only 31% of patients received AA therapy consistent with ACCF/AHA guidelines.
  • 35% of patients were discharged on an AA; 75.6% of those not on AA had no contraindications.
  • No significant difference in 30- or 90-day readmission rates between AA and non-AA groups.

Conclusions:

  • Aldosterone antagonists remain underutilized in heart failure management.
  • A significant gap exists between guideline recommendations and clinical practice for AA prescription.
  • Further research may be needed to understand factors contributing to underuse and its impact on readmissions.

Keywords:
aldosterone antagonistsheart failureunderuse

More Related Videos

Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
966
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
402
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
369